|
“We are incredibly pleased with these trial results, which represent an vital milestone for the product and demonstrate its possible value in the treatment of complex skin infections, especially those caused by methicillin-resistant Staphlococcus aureus,” said June Almenoff M.D., Ph.D., president and chief medical officer of Furiex. “Because of emerging resistance to established antibiotics, there is really a big unmet want for antibiotics for instance JNJ-Q2, which cover a broad range of pathogens, such as resistant staph and strep, and which have the potential for both IV and oral use. JNJ-Q2′s demonstrated ability to treat severe skin infections successfully as an oral agent differentiates it from numerous other products for MRSA, which require intravenous treatment.”
|
